inVentiv Health, a global provider of clinical, commercial and consulting services, announced that its existing CRO, PharmaNet/i3, will be renamed inVentiv Health Clinical. This renaming reflects the closer alignment between the clinical segment and inVentiv's commercial and consulting services.
"As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services," said Paul Meister, CEO of inVentiv Health. "Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialization."
"By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry," said Raymond Hill, who was appointed in December 2012 to lead inVentiv Health Clinical.. "One example is our ability to assist clients in late stage trials by tapping both digital and adherence experts from other inVentiv companies. Through this approach we can help our clients simplify complex health economics and outcomes research trials."
inVentiv Health Clinical is a CRO offering early stage (phase I), phase II-III, late stage (phase IV) clinical development and clinical staffing services to healthcare companies worldwide. These services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to late stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department.
"Healthcare companies are continuing to increase their reliance on CROs," said Hill. "With 7,000 employees in more than 36 countries across the world, inVentiv Health Clinical has the breadth of experience in geographies and the necessary therapeutic expertise to meet the challenges that our clients are facing."
